Promosyon programı Y-mAbs Therapeutics, Inc.
Şirket hakkında
Y-mAbs Therapeutics, Inc., биофармацевтическая компания на клинической стадии, специализируется на разработке и коммерциализации новых терапевтических продуктов на основе антител для лечения рака в Соединенных Штатах. Компания разрабатывает накситамаб, который находится в фазе 2 клинических испытаний для лечения педиатрических пациентов с рецидивирующей стеосаркомой или рефрактерной нейробластомой высокого риска, а также с другими GD2-положительными опухолями; и вакцина GD2-GD3, которая находится в фазе 2 клинических испытаний для лечения нейробластомы высокого риска.
Daha fazla ayrıntıP/BV | 5.42 |
---|---|
EV/EBITDA | -10.53 |
EBITDA | -0.0828 |
Цена ао | 14.66 |
P/S | 95.72 |
Сайт | http://www.ymabs.com |
Число акций ао | 0.04365 млрд |
Выручка | 0.0208 |
Див.доход ао | 0 |
ISIN | US9842411095 |
P/E | 150.78 |
Валюта | usd |
IPO date | 2018-09-21 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Günlük fiyat değişimi: | 0% (10.56) |
---|---|
Haftalık fiyat değişimi: | -2.76% (10.86) |
Aylık fiyat değişimi: | -27.07% (14.48) |
3 ayda fiyat değişimi: | -31.38% (15.39) |
Altı ayda fiyat değişimi: | -12.07% (12.01) |
Yıllık fiyat değişimi: | +82.07% (5.8) |
3 yılda fiyat değişimi: | -35.41% (16.35) |
5 yılda fiyat değişimi: | -63.18% (28.68) |
Yılbaşından bu yana fiyat değişimi: | +42.32% (7.42) |
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
Kurumlar | Hacim | Paylaşmak, % |
---|---|---|
Blackrock Inc. | 2917080 | 6.66 |
Vanguard Group Inc | 2244238 | 5.13 |
Sofinnova Investments, Inc. | 2194278 | 5.01 |
Polar Capital Holdings PLC | 2056872 | 4.7 |
Shaw D.E. & Co., Inc. | 1323780 | 3.02 |
Caligan Partners, LP | 1048425 | 2.39 |
Acadian Asset Management. LLC | 802381 | 1.83 |
State Street Corporation | 761532 | 1.74 |
Geode Capital Management, LLC | 738548 | 1.69 |
BOOTHBAY FUND MANAGEMENT, LLC | 694094 | 1.59 |
ETF | Paylaşmak, % | Yıllık karlılık, % | Temettüler, % |
---|---|---|---|
First Trust Active Factor Small Cap ETF | 0.41218 | 34.251150665961 | 1.61948 |
Avantis U.S. Equity ETF | 0.00033 | 32.224830464267 | 1.59151 |
Virtus LifeSci Biotech Products ETF | 1.68335 | 36.788704846892 | 0.13953 |
ProShares Ultra Nasdaq Biotechnology | 0.03957 | 51.697637072723 | 0.85651 |
ProShares UltraShort Nasdaq Biotechnology | 0.16 | -40.363937138131 | 1.76 |
Range Cancer Therapeutics ETF | 1.23672 | 47.24446537918 | 0.11955 |
Dimensional U.S. Core Equity 2 ETF | 0.00277 | 30.755198832543 | 1.47098 |
Dimensional US Core Equity Market ETF | 0.00068 | 30.983243755928 | 1.40618 |
Dimensional U.S. Equity ETF | 0.00067 | 31.530984204131 | 1.3557 |
Fidelity MSCI Health Care Index ETF | 0.006 | 13.390080209527 | 1.46057 |
Franklin U.S. Small Cap Multifactor Index ETF | 0.03276 | 26.989243663262 | 1.90721 |
Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.07415 | 31.359936575053 | 1.41955 |
ProShares Hedge Replication ETF | 0.00307 | 5.9237999659878 | 1.47892 |
Humankind US Stock ETF | 0.00336 | 18.809430395549 | 1.99919 |
Invesco Nasdaq Biotechnology ETF | 0.05904 | 28.578975171685 | 0.8565 |
iShares Morningstar Small-Cap ETF | 0.0081 | 30.095066471445 | 1.60498 |
iShares Morningstar Small-Cap Growth ETF | 0.01046 | 33.628071953382 | 0.72598 |
iShares Morningstar Small Cap Value ETF | 0.00625 | 26.701717953559 | 2.50476 |
iShares Micro-Cap ETF | 0.12811 | 36.318555985322 | 1.54048 |
iShares Russell 2000 Growth ETF | 0.03741 | 38.042556988 | 0.6026 |
iShares Russell 3000 ETF | 0.00085 | 32.57283798366 | 1.43482 |
iShares Morningstar Small-Cap ETF | 0.0081 | 391.25300933451 | 1.60498 |
iShares Morningstar Small-Cap Growth ETF | 0.01046 | 680.05582339508 | 0.72598 |
iShares Morningstar Small-Cap Value ETF | 0.00625 | 227.12514109528 | 2.50476 |
Principal U.S. Small-Cap ETF | 0.03438 | 35.926993275696 | 1.20466 |
Schwab U.S. Small-Cap ETF | 0.01042 | 34.281650071124 | 1.51433 |
Schwab U.S. Broad Market ETF | 0.00074 | 32.5 | 1.43354 |
SPDR Portfolio MSCI Global Stock Market ETF | 0.00189 | 23.600605143722 | 2.19607 |
ProShares UltraPro Russell2000 | 0.01091 | 89.821266282945 | 1.47873 |
Vanguard U.S. Momentum Factor ETF | 0.11 | 45.845704753962 | 1.05834 |
Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
Vanguard Russell 2000 Growth ETF | 0.04 | 39.350070246167 | 0.60264 |
Vanguard Russell 2000 ETF | 0.02 | 35.648084105685 | 1.48801 |
Principal Healthcare Innovators ETF | 0.06039 | 618.4964157054 | 0.8416 |
Future Tech ETF | 0.06039 | 426.33969118983 | 0.8416 |
Süpervizör | İş unvanı | Ödeme | Doğum yılı |
---|---|---|---|
Mr. Thomas Gad | Founder, Chief Business Officer & Vice Chairman | 1.05M | 1970 (54 yıl) |
Mr. Joris Wiel Jan Wilms | Senior VP & COO | N/A | 1974 (50 yıllar) |
Dr. Vignesh Rajah M.B.A., MBBS | Senior VP & Chief Medical Officer | 406.27k | 1965 (59 yıllar) |
Dr. Torben Lund-Hansen M.Sc., Ph.D. | Senior VP & CTO | N/A | 1951 (73 yıl) |
Ms. Susan Smith | Senior VP & Chief Commercial Officer | 710k | 1971 (53 yıl) |
Mr. Michael Rossi | CEO, President & Director | N/A | 1971 (53 yıl) |
Ms. Courtney Dugan | Vice President of Investor Relations | N/A | |
Mr. Peter P. Pfreundschuh CPA | CFO & Treasurer | 1969 (55 yıllar) | |
Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Development Officer | 1948 (76 yıllar) |
Web sitesi: http://www.ymabs.com